Sanofi, GSK to provide coronavirus vaccine to global coalition

close

Video

Coronavirus vaccines, treatments: How hopeful can Americans be?

Fox News medical contributor Dr. Janette Nesheiwat discusses the advancement of COVID-19 treatment for Americans and weighs in on Trump, Biden plans to combat the virus.

LONDON – Drugmakers Sanofi and GlaxoSmithKline have agreed to provide 200 million doses of their potential COVID-19 vaccine to the COVAX Facility, a collaboration designed to give countries around the world equal access to coronavirus vaccines.

The Sanofi-GSK vaccine candidate is in early stage trials, with results expected in early December. The drugmakers said Wednesday that they plan to begin phase three trial by the end of the year and request regulatory approval of the vaccine in the first half of 2021.

EU WON'T SEE FULL CORONAVIRUS VACCINATION UNTIL 2022, OFFICIAL REPORTEDLY WARNS

The facility is part of COVAX, a coalition of governments, health organizations, businesses and charities working to accelerate the development of COVID-19 vaccines.

CORONAVIRUS HOSPITALIZATIONS IN THIS STATE HIT ANOTHER RECORD HIGH

Thomas Triomphe, head of Sanofi’s vaccine unit, said: ”To address a global health crisis of this magnitude, it takes unique partnerships. The commitment we are announcing today for the COVAX Facility can help us together stand a better chance of bringing the pandemic under control.”

CLICK HERE FOR COMPLETE CORONAVIRUS COVERAGE

Almost 44 million people have been confirmed to be infected with the virus worldwide and 1.16 million of them have died, according to a tally by Johns Hopkins University. Experts say the true toll of the pandemic is much greater than that, due to limited testing, missed mild cases and concealment of cases by some governments.